Dare Bioscience Net Worth
Dare Bioscience Net Worth Breakdown | DARE |
Dare Bioscience Net Worth Analysis
Dare Bioscience's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dare Bioscience's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dare Bioscience's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dare Bioscience's net worth analysis. One common approach is to calculate Dare Bioscience's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dare Bioscience's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dare Bioscience's net worth. This approach calculates the present value of Dare Bioscience's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dare Bioscience's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dare Bioscience's net worth. This involves comparing Dare Bioscience's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dare Bioscience's net worth relative to its peers.
Enterprise Value |
|
To determine if Dare Bioscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dare Bioscience's net worth research are outlined below:
| Dare Bioscience generated a negative expected return over the last 90 days | |
| Dare Bioscience has high historical volatility and very poor performance | |
| Dare Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.78 K. Net Loss for the year was (4.05 M) with loss before overhead, payroll, taxes, and interest of (14.32 M). | |
| Dare Bioscience has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Dare Bioscience Upgraded at Wall Street Zen |
Dare Bioscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dare Bioscience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dare Bioscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Dare Bioscience Target Price Consensus
Dare target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Dare Bioscience's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Dare analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Dare stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Dare Bioscience, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDare Bioscience Target Price Projection
Dare Bioscience's current and average target prices are 2.02 and 11.67, respectively. The current price of Dare Bioscience is the price at which Dare Bioscience is currently trading. On the other hand, Dare Bioscience's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Dare Bioscience Market Quote on 30th of August 2025
Target Price
Analyst Consensus On Dare Bioscience Target Price
Know Dare Bioscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dare Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dare Bioscience backward and forwards among themselves. Dare Bioscience's institutional investor refers to the entity that pools money to purchase Dare Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hanson Mcclain Inc | 2025-03-31 | 1.7 K | Tower Research Capital Llc | 2025-06-30 | 1.4 K | Ifs Advisors, Llc | 2025-06-30 | 950 | Sbi Securities Co Ltd | 2025-03-31 | 575 | Bank Of America Corp | 2025-03-31 | 87.0 | Mather Group, Inc. | 2025-03-31 | 84.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 25.0 | Jpmorgan Chase & Co | 2025-03-31 | 19.0 | Caldwell Sutter Capital Inc | 2025-06-30 | 17.0 | Vanguard Group Inc | 2025-06-30 | 328.3 K | Amh Equity Ltd | 2025-06-30 | 193.6 K |
Follow Dare Bioscience's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 27.23 M.Market Cap |
|
Project Dare Bioscience's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (47.65) | (45.27) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | 0.67 | 0.71 |
When accessing Dare Bioscience's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dare Bioscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dare Bioscience's profitability and make more informed investment decisions.
Please note, the presentation of Dare Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dare Bioscience's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Dare Bioscience's management manipulating its earnings.
Evaluate Dare Bioscience's management efficiency
Dare Bioscience has return on total asset (ROA) of (0.6313) % which means that it has lost $0.6313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.9469) %, meaning that it created substantial loss on money invested by shareholders. Dare Bioscience's management efficiency ratios could be used to measure how well Dare Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.71, whereas Return On Tangible Assets are forecasted to decline to (0.19). At present, Dare Bioscience's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.2 M, whereas Other Assets are forecasted to decline to 0.86.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.71) | (0.74) | |
| Tangible Book Value Per Share | (0.71) | (0.74) | |
| Enterprise Value Over EBITDA | (0.52) | (0.54) | |
| Price Book Value Ratio | (4.41) | (4.63) | |
| Enterprise Value Multiple | (0.52) | (0.54) | |
| Price Fair Value | (4.41) | (4.63) | |
| Enterprise Value | 32.8 M | 34.4 M |
The strategic initiatives led by Dare Bioscience's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 490.6986 | Revenue | Quarterly Revenue Growth 1.734 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dare Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dare Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dare Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dare Bioscience time-series forecasting models is one of many Dare Bioscience's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dare Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Dare Bioscience Earnings Estimation Breakdown
The calculation of Dare Bioscience's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Dare Bioscience is estimated to be -0.3567 with the future projection ranging from a low of -0.41 to a high of -0.32. Please be aware that this consensus of annual earnings estimates for Dare Bioscience is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.41 Lowest | Expected EPS | -0.32 Highest |
Dare Bioscience Earnings Projection Consensus
Suppose the current estimates of Dare Bioscience's value are higher than the current market price of the Dare Bioscience stock. In this case, investors may conclude that Dare Bioscience is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Dare Bioscience's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of September 2025 | Current EPS (TTM) | |
| 4 | 61.03% | -0.45 | -0.3567 | -2.16 |
Dare Bioscience Earnings per Share Projection vs Actual
Actual Earning per Share of Dare Bioscience refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Dare Bioscience predict the company's earnings will be in the future. The higher the earnings per share of Dare Bioscience, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Dare Bioscience Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Dare Bioscience, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Dare Bioscience should always be considered in relation to other companies to make a more educated investment decision.Dare Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Dare Bioscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-08-14 | 2025-06-30 | 0.03 | -0.45 | -0.48 | 1600 | ||
2025-05-05 | 2025-03-31 | -0.58 | -0.5 | 0.08 | 13 | ||
2025-03-26 | 2024-12-31 | -0.6333 | -0.65 | -0.0167 | 2 | ||
2024-11-07 | 2024-09-30 | -0.73 | -0.55 | 0.18 | 24 | ||
2024-08-08 | 2024-06-30 | 0.02 | -0.88 | -0.9 | 4500 | ||
2024-05-14 | 2024-03-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2024-03-28 | 2023-12-31 | -0.1 | -0.06 | 0.04 | 40 | ||
2023-11-09 | 2023-09-30 | -0.1 | -0.09 | 0.01 | 10 | ||
2023-08-10 | 2023-06-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2023-05-11 | 2023-03-31 | -0.1 | -0.09 | 0.01 | 10 | ||
2023-03-30 | 2022-12-31 | -0.14 | -0.19 | -0.05 | 35 | ||
2022-11-10 | 2022-09-30 | -0.12 | -0.08 | 0.04 | 33 | ||
2022-08-09 | 2022-06-30 | -0.06 | 0.0048 | 0.0648 | 108 | ||
2022-05-12 | 2022-03-31 | -0.14 | -0.1 | 0.04 | 28 | ||
2022-03-31 | 2021-12-31 | -0.15 | -0.18 | -0.03 | 20 | ||
2021-11-10 | 2021-09-30 | -0.13 | -0.18 | -0.05 | 38 | ||
2021-08-12 | 2021-06-30 | -0.16 | -0.18 | -0.02 | 12 | ||
2021-05-13 | 2021-03-31 | -0.22 | -0.17 | 0.05 | 22 | ||
2021-03-30 | 2020-12-31 | -0.13 | -0.28 | -0.15 | 115 | ||
2020-11-12 | 2020-09-30 | -0.17 | -0.24 | -0.07 | 41 | ||
2020-08-12 | 2020-06-30 | -0.15 | -0.27 | -0.12 | 80 | ||
2020-05-14 | 2020-03-31 | -0.29 | -0.18 | 0.11 | 37 | ||
2020-03-27 | 2019-12-31 | -0.18 | -0.21 | -0.03 | 16 | ||
2019-11-12 | 2019-09-30 | -0.21 | -0.2 | 0.01 | 4 | ||
2019-08-14 | 2019-06-30 | -0.2 | -0.29 | -0.09 | 45 | ||
2019-04-01 | 2019-03-31 | -0.27 | -0.25 | 0.02 | 7 | ||
2019-03-31 | 2018-12-31 | -0.27 | -0.25 | 0.02 | 7 | ||
2018-11-13 | 2018-09-30 | -0.24 | -0.23 | 0.01 | 4 | ||
2018-08-13 | 2018-06-30 | -0.23 | -0.32 | -0.09 | 39 | ||
2018-05-14 | 2018-03-31 | -0.88 | -0.88 | 0.0 | 0 | ||
2018-03-28 | 2017-12-31 | -3.1 | -1.48 | 1.62 | 52 | ||
2017-05-12 | 2017-03-31 | -3.1 | -2.7 | 0.4 | 12 | ||
2017-03-31 | 2016-12-31 | -3.35 | -1.6 | 1.75 | 52 | ||
2016-11-03 | 2016-09-30 | -4.08 | -3.6 | 0.48 | 11 | ||
2016-08-04 | 2016-06-30 | -4.81 | -4.0 | 0.81 | 16 | ||
2016-05-02 | 2016-03-31 | -4.26 | -4.9 | -0.64 | 15 | ||
2016-03-10 | 2015-12-31 | -4.09 | -3.9 | 0.19 | 4 | ||
2015-11-16 | 2015-09-30 | -4.13 | -3.9 | 0.23 | 5 | ||
2015-08-06 | 2015-06-30 | -4.25 | -3.7 | 0.55 | 12 | ||
2015-05-06 | 2015-03-31 | -4.82 | -4.1 | 0.72 | 14 | ||
2015-03-19 | 2014-12-31 | -4.92 | -3.4 | 1.52 | 30 | ||
2014-11-13 | 2014-09-30 | -3.97 | -2.8 | 1.17 | 29 | ||
2014-08-12 | 2014-06-30 | -3.6 | -2.9 | 0.7 | 19 | ||
2014-05-27 | 2014-03-31 | -2.97 | -37.0 | -34.03 | 1145 |
Dare Bioscience Corporate Management
| David Friend | Chief Officer | Profile | |
| MarDee HaringLayton | Chief Officer | Profile | |
| John Fair | Chief Business Officer | Profile | |
| Lisa WaltersHoffert | Executive Officer | Profile | |
| Mark Walters | Vice Operations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dare Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dare Bioscience. If investors know Dare will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dare Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share | Quarterly Revenue Growth 1.734 | Return On Assets | Return On Equity |
The market value of Dare Bioscience is measured differently than its book value, which is the value of Dare that is recorded on the company's balance sheet. Investors also form their own opinion of Dare Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Dare Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dare Bioscience's market value can be influenced by many factors that don't directly affect Dare Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dare Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Dare Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dare Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.